IRMD IRADIMED CORP

Nasdaq iradimed.com


$ 86.41 $ 1.79 (2.11 %)    

Wednesday, 12-Nov-2025 15:59:54 EST
QQQ $ 613.20 $ -4.34 (-0.7 %)
DIA $ 481.61 $ 0.21 (0.04 %)
SPY $ 677.85 $ -2.69 (-0.4 %)
TLT $ 89.89 $ 0.07 (0.08 %)
GLD $ 385.02 $ -2.27 (-0.59 %)
$ 86.43
$ 84.50
$ 85.00 x 3
$ 87.85 x 1
-- - --
$ 47.21 - $ 87.88
41,688
na
1.1B
$ 0.78
$ 51.90
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-01-2025 06-30-2025 10-Q
3 05-05-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 03-01-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-02-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-05-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 03-04-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-05-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-06-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-07-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-08-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-06-2017 09-30-2017 10-Q
34 08-04-2017 06-30-2017 10-Q
35 05-05-2017 03-31-2017 10-Q
36 03-10-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 03-10-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 iradimed-sees-q4-gaap-eps-043-047-vs-041-est

iRadimed (NASDAQ:IRMD) is looking for Q4 GAAP EPS of $0.43-$0.47 vs $0.41 analyst estimate..

 iradimed-sees-q4-adj-eps-047-051-vs-047-est-sees-sales-21400m-22400m-vs-20733m-est

iRadimed (NASDAQ:IRMD) is looking for Q4 Adj EPS of $0.47-$0.51 vs $0.47 analyst estimate. sees sales of $21.400 million-$22.40...

 iradimed-raises-fy2025-gaap-eps-guidance-from-160-170-to-168-172-vs-165-est

iRadimed (NASDAQ:IRMD) raises FY2025 GAAP EPS guidance from $1.60-$1.70 to $1.68-$1.72 vs $1.65 analyst estimate..

 iradimed-raises-fy2025-adj-eps-guidance-from-176-186-to-184-188-vs-182-est-raises-fy2025-sales-guidance-from-80000m-82500m-to-82500m-83500m-vs-81091m-est

iRadimed (NASDAQ:IRMD) raises FY2025 Adj EPS guidance from $1.76-$1.86 to $1.84-$1.88 vs $1.82 analyst estimate. Raises FY2025 ...

 iradimed-q3-adj-eps-047-beats-046-estimate-sales-21202m-beat-20498m-estimate

iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.46 by 3.3...

 preview-iradimeds-earnings
Preview: iRadimed's Earnings
10/31/2025 20:01:31

 earnings-preview-iradimed
Earnings Preview: iRadimed
07/31/2025 18:02:49

 iradimed-sees-q2-adj-eps-041-044-vs-043-est-sees-sales-19700m-19900m-vs-1981m-est

iRadimed (NASDAQ:IRMD) is looking for Q2 Adj EPS of $0.41-$0.44 vs $0.43 analyst estimate. sees sales of $19.700 million-$19.90...

 iradimed-affirms-fy2025-gaap-eps-guidance-of-155-165-vs-164-est

iRadimed (NASDAQ:IRMD) affirms FY2025 GAAP EPS guidance from $1.55-$1.65 to $1.55-$1.65 vs $1.64 analyst estimate..

 iradimed-sees-q2-gaap-eps-037-040-vs-041-est

iRadimed (NASDAQ:IRMD) is looking for Q2 GAAP EPS of $0.37-$0.40 vs $0.41 analyst estimate..

 iradimed-affirms-fy2025-adj-eps-guidance-of-171-181-vs-175-est-affirms-fy2025-sales-guidance-of-7800m-8200m-vs-7941m-est

iRadimed (NASDAQ:IRMD) affirms FY2025 Adj EPS guidance from $1.71-$1.81 to $1.71-$1.81 vs $1.75 analyst estimate. Affirms FY202...

 iradimed-q1-adj-eps-042-beats-041-estimate-sales-1951m-beat-1933m-estimate

iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.41 by 2.4...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION